
À propos de ce podcast
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video…
72 épisodes · Business
The BioCentury Show
À propos de ce podcast
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video…
Épisodes récents
- Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile18 sept. · 35 min
- Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets4 sept. · 32 min
- Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient21 août · 30 min
- Ep. 116 - Ovid's Jeremy Levin on biotech in the balance7 août · 33 min
- Ep. 115 - Initiate's Owens on what it takes to be AI-native23 juil. · 40 min
- Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model10 juil. · 42 min
- Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking25 juin · 35 min
- Ep. 112 - Chris Arendt on rebuilding Takeda for AI18 juin · 40 min
- Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner12 juin · 37 min
- Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China28 mai · 38 min